Steven L.  Fasman net worth and biography

Steven Fasman Biography and Net Worth

SVP of Catalent
Steven Fasman was named Senior Vice President and General Counsel in October 2014. Prior to that, he served as Executive Vice President-Law of MacAndrews & Forbes Holdings Inc., a privately held diversified holding company, from January 2012 to March 2014. Before that, Mr. Fasman held various positions at MacAndrews & Forbes Holdings since 1992 of increasing responsibility.

From 2008 through March 2014, he also served as General Counsel and Chief Compliance Officer of M & F Worldwide Corp., a holding company with interests in financial products, customer calling centers, staffing operations, educational software and flavoring products.

From 2008 to 2011, Mr. Fasman also served as a director of SIGA Technologies, Inc., a biodefense company.

Mr. Fasman spent his early career at the law firm of Paul, Weiss, Rifkind, Wharton & Garrison, where he focused on domestic and international litigation and regulatory proceedings.

Mr. Fasman holds a law degree from Yale University and an A.B. degree in mathematics from Princeton University. Mr. Fasman is a trustee of the Jewish Board of Family & Children’s Services in New York City.

What is Steven L. Fasman's net worth?

The estimated net worth of Steven L. Fasman is at least $2.74 million as of August 24th, 2023. Mr. Fasman owns 73,789 shares of Catalent stock worth more than $2,743,475 as of December 9th. This net worth approximation does not reflect any other investments that Mr. Fasman may own. Learn More about Steven L. Fasman's net worth.

How do I contact Steven L. Fasman?

The corporate mailing address for Mr. Fasman and other Catalent executives is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. Catalent can also be reached via phone at (732) 537-6200 and via email at [email protected]. Learn More on Steven L. Fasman's contact information.

Has Steven L. Fasman been buying or selling shares of Catalent?

Steven L. Fasman has not been actively trading shares of Catalent in the last ninety days. Learn More on Steven L. Fasman's trading history.

Who are Catalent's active insiders?

Catalent's insider roster includes Jonathan Arnold (Insider), Thomas Castellano (CFO), John Chiminski (CEO), Steven Fasman (SVP), Karen Flynn (Insider), Mario Gargiulo (SVP), Aristippos Gennadios (Insider), John Greisch (Insider), Michael Grippo (SVP), Scott Gunther (SVP), Thomas Hawkeswood (Insider), Ricky Hopson (CAO), Wetteny Joseph (CFO), Charles Lickfold (SVP), Gregory Lucier (Director), Alessandro Maselli (COO), Ricardo Pravda (SVP), Michael Riley (Insider), Michelle Ryan (Director), Kay Schmidt (SVP), Ricci Whitlow (Insider), and Peter Zippelius (Director). Learn More on Catalent's active insiders.

Are insiders buying or selling shares of Catalent?

In the last year, Catalent insiders bought shares 2 times. They purchased a total of 22,000 shares worth more than $1,105,020.00. In the last year, insiders at the sold shares 10 times. They sold a total of 8,209 shares worth more than $385,218.07. The most recent insider tranaction occured on August, 31st when Director Michelle R Ryan bought 1,000 shares worth more than $49,980.00. Insiders at Catalent own 0.6% of the company. Learn More about insider trades at Catalent.

Information on this page was last updated on 8/31/2023.

Steven L. Fasman Insider Trading History at Catalent

See Full Table

Steven L. Fasman Buying and Selling Activity at Catalent

This chart shows Steven L. Fasman's buying and selling at Catalent by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Catalent Company Overview

Catalent logo
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Read More

Today's Range

Now: $37.18
Low: $37.11
High: $37.87

50 Day Range

MA: $39.84
Low: $32.17
High: $46.57

2 Week Range

Now: $37.18
Low: $31.45
High: $74.49


1,247,523 shs

Average Volume

1,953,786 shs

Market Capitalization

$6.70 billion

P/E Ratio


Dividend Yield